Navigation Links
Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
Date:2/21/2008

ription volume.

- Launch has been tracking in line with other blockbuster Central Nervous System drug launches.

- Over 900,000 prescriptions since launch.

- Over 50% (23,000) of high volume physicians prescribing.

- Coupons are now less than 15% of total prescriptions.

- ADDERALL XR(R) - ADHD - Sales for 2007 were up 19% to $1,030.9 million (2006: $863.6 million).

- DAYTRANA(TM) - ADHD.

- Sales for 2007 were up 156% to $64.2 million (2006: $25.1 million).

- On January 9, 2008 the FDA issued a Warning Letter to Noven Pharmaceuticals Inc. ("Noven") which related to Noven's manufacture of DAYTRANA. Further regulatory action could result if the FDA's concerns are not satisfied fully. Noven submitted a response to the FDA on January 30, 2008.

- LIALDA(TM)/MEZAVANT(R) - Ulcerative Colitis.

- LIALDA, the only once-daily oral formulation of mesalamine was approved by the FDA in January 2007 and launched in the US in March 2007, acquiring 8.0% share of the US oral mesalamine market at December 31, 2007. Sales for 2007 were $50.5 million.

- Shire's share of the US oral mesalamine market from LIALDA and PENTASA(R) combined was 26.0% at February 8, 2008.

- The product was launched in the UK in November 2007 as MEZAVANT XL, with further launches planned in the EU in 2008. It was launched in Canada on January 28, 2008 as MEZAVANT.

- FOSRENOL(R) - Hyperphosphatemia - International launches continued and FOSRENOL is now available in 24 countries with worldwide sales in 2007 of $102.2 million (2006: $44.8 million).

- DYNEPO(R) - Anemia associated with chronic kidney disease ("CKD") - DYNEPO is the first and only erythropoiesis-stimulating agent produced in a human cell line. The product has been launched in several EU countries and sales for 2007 were $14.2 million.

- ELAPRASE(R) - Hunter syndrome.

- On February 11, 2008 ELAPRASE was approved for commercial sale by the Mex
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Correction Re Website
2. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
3. Shire Engages Palio
4. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
5. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
6. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire plc: Board Changes
9. David Mott Appointed Non Executive Director at Shire
10. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
11. Shire Divests Non-Core Product Portfolio to Almirall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... -- MEI Pharma, Inc. (Nasdaq: MEIP ), an oncology ... cancer, announced today that Daniel P. Gold , Ph.D., ... NewsMakers in the Biotech Industry conference on Friday, September ... Broadway Hotel & Conference Center in New York ... accessed at www.meipharma.com . A replay will be available ...
(Date:9/18/2014)... 18 septembre 2014 Mapi, société créée ... 1974, a été depuis 40 ans l,un ... cliniques traditionnelles par des évaluations recentrées sur ... les impacts économiques des traitements. ... A cours d,une récente conférence téléphonique ...
(Date:9/18/2014)... SeqLL Inc., the owner of ... today the closing of a $1M Series-A funding ... Diagnostic Technologies, will increase the power of tSMS™ ... in March 2013 by Daniel Jones, a former ... BioSciences, SeqLL has continued to offer Helicos’ sequencing ...
(Date:9/18/2014)... sweeteners, promoted as aids to weight loss and diabetes ... and metabolic disease; and they do it in a ... the gut microbiota the substantial population of bacteria ... experiments in mice and humans, were published today in ... Elinav of the Weizmann Institute,s Immunology Department, who led ...
Breaking Biology Technology:MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 31974 - 2014 - Mapi fête ses 40 ans 2SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2Gut bacteria, artificial sweeteners and glucose intolerance 2Gut bacteria, artificial sweeteners and glucose intolerance 3
... Sweden, July 14 PharmaSurgics AB.,successfully completes Phase ... is safe and well tolerated. Initially developed to ... combines,the pharmacological effect of PXL01 with the physical ... to be the first anti-adhesion drug on the,market. ...
... LA JOLLA, Calif., July 14 Synthetic Genomics ... solutions to address a variety of global challenges including ... and development agreement with ExxonMobil Research and Engineering Company ... algae. , , ...
... , ... today announced clearance for marketing by the United States Food and Drug Administration (K083292) ... , ... 14, 2009 -- EMcision Ltd. today announced clearance for marketing by the United States ...
Cached Biology Technology:Novel Product for the Prevention of Post-Surgical Adhesion Formation Completes Phase I Clinical Study 2Synthetic Genomics Inc. and ExxonMobil Research and Engineering Company Sign Exclusive, Multi-Year Agreement to Develop Next Generation Biofuels Using Photosynthetic Algae 2Synthetic Genomics Inc. and ExxonMobil Research and Engineering Company Sign Exclusive, Multi-Year Agreement to Develop Next Generation Biofuels Using Photosynthetic Algae 3EMcision Announces 510(k) Clearance of the Habib EndoHPB, its Novel Bipolar RF Device for the Palliation of Biliary and Pancreatic Tumours 2
(Date:9/17/2014)... four-year project, delivering its first release in 2004. After ... several EC projects, as a part of the EC-FP7 ... to increase the general awareness of the work done ... of the Fauna Europaea results, the Biodiversity ... tools to prepare data papers for all 56 major ...
(Date:9/17/2014)... developed, very cleverly, some lessons on how to create ... Joseph Shaw, director of the Optical Technology Center at ... at the nanoscale, we,ll discover them." , Some of ... during a conference called "The Nature of Light: Light ... the University of Arizona College of Optical Sciences. The ...
(Date:9/17/2014)... New research from the Copenhagen Centre for Social Evolution ... evolutionary theory that birth weight and -length can partially ... disorders such as autism and schizophrenia later in life. ... births, and subsequent hospital diagnoses for up to 30 ... factors. The study is published today in the ...
Breaking Biology News(10 mins):Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2Nature's designs inspire research into new light-based technologies 2Nature's designs inspire research into new light-based technologies 3Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3
... -- Traditionally addressed through hand-weeding and/or herbicide application, controlling ... production. Increased labor costs have made hand-weeding prohibitive as ... may be effective and less expensive, non-target herbicide loss ... the environment. To address the economic and environmental impact ...
... -- Associate Professor Paul Blowers of the University of ... 2011 Arizona Professor of the Year, recognized for commitment ... Advancement of Teaching and the Council for Advancement and ... announced the award on Nov. 17 in Washington, D.C. ...
... CAMBRIDGE, Mass. -- Significant progress has been ... psychiatric disease. Recent studies have identified common genetic ... significant risk. One example of a rare cause ... (DISC1) gene, first identified in a large Scottish ...
Cached Biology News:Biodegradable mulches successfully control weeds in container-grown arborvitae 2Arizona Engineering associate professor earns national recognition 2Picower: Schizophrenia gene associated with psychiatric disorders and brain development 2Picower: Schizophrenia gene associated with psychiatric disorders and brain development 3
... The MEGAscript RNAi Kit is ... large mass amounts of ready-to-use ... non-mammalian systems. The MEGAscript RNAi ... patented high-yield transcription technol-ogy and ...
UGT1A6 (D-20)...
... With its patented technology, the Lone Wolf ... any Normally Open proportional valve available on ... operation, provides repeatable high-speed performance, and ensures ... , Enhances system control and patient ...
Normal Hamster Serum...
Biology Products: